FibroGen Inc (FGEN)
0.3921
0.00 (0.00%)
USD |
NASDAQ |
Nov 22, 11:00
FibroGen Enterprise Value: 22.76M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 22.76M |
| November 20, 2024 | 19.01M |
| November 19, 2024 | 19.01M |
| November 18, 2024 | 17.74M |
| November 15, 2024 | 17.47M |
| November 14, 2024 | 21.02M |
| November 13, 2024 | 17.22M |
| November 12, 2024 | 22.70M |
| November 11, 2024 | 17.86M |
| November 08, 2024 | 16.29M |
| November 07, 2024 | 15.26M |
| November 06, 2024 | 15.02M |
| November 05, 2024 | 14.68M |
| November 04, 2024 | 16.53M |
| November 01, 2024 | 15.88M |
| October 31, 2024 | 14.12M |
| October 30, 2024 | 15.77M |
| October 29, 2024 | 14.60M |
| October 28, 2024 | 13.85M |
| October 25, 2024 | 14.78M |
| October 24, 2024 | 15.99M |
| October 23, 2024 | 15.99M |
| October 22, 2024 | 19.04M |
| October 21, 2024 | 21.48M |
| October 18, 2024 | 23.19M |
| Date | Value |
|---|---|
| October 17, 2024 | 23.55M |
| October 16, 2024 | 21.60M |
| October 15, 2024 | 19.46M |
| October 14, 2024 | 18.32M |
| October 11, 2024 | 19.75M |
| October 10, 2024 | 17.70M |
| October 09, 2024 | 16.77M |
| October 08, 2024 | 16.84M |
| October 07, 2024 | 18.27M |
| October 04, 2024 | 20.70M |
| October 03, 2024 | 23.94M |
| October 02, 2024 | 24.04M |
| October 01, 2024 | 23.24M |
| September 30, 2024 | 23.99M |
| September 27, 2024 | 14.53M |
| September 26, 2024 | 13.05M |
| September 25, 2024 | 11.18M |
| September 24, 2024 | 12.25M |
| September 23, 2024 | 11.09M |
| September 20, 2024 | 14.75M |
| September 19, 2024 | 15.50M |
| September 18, 2024 | 15.90M |
| September 17, 2024 | 18.72M |
| September 16, 2024 | 19.13M |
| September 13, 2024 | 20.92M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-145.12M
Minimum
Sep 22 2023
4.434B
Maximum
Feb 12 2021
1.300B
Average
918.66M
Median
Feb 23 2022
Enterprise Value Benchmarks
| Biomarin Pharmaceutical Inc | 11.76B |
| Arbutus Biopharma Corp | 527.85M |
| GlycoMimetics Inc | 6.243M |
| Cidara Therapeutics Inc | -4.423M |
| Cue Biopharma Inc | 38.12M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.08M |
| Revenue (Quarterly) | 46.33M |
| Total Expenses (Quarterly) | 44.56M |
| EPS Diluted (Quarterly) | -0.17 |
| Gross Profit Margin (Quarterly) | 88.57% |
| Profit Margin (Quarterly) | -36.87% |
| Earnings Yield | -313.7% |
| Normalized Earnings Yield | -276.50 |